Vaxart (VXRT) Q2 2024 earnings summary

Executive summary

• Advanced COVID-19 and norovirus vaccine programs, securing up to $453 million in BARDA funding and reporting positive clinical trial results for norovirus.

• Leadership emphasized strategic focus on oral pill vaccine technology and achieving key 2024 milestones.

• Received constructive FDA feedback and completed equity offerings raising $56.3 million net in H1 2024.

• Cash runway extended into 2026, supporting execution of regulatory and clinical milestones.

Financial highlights

• Q2 2024 revenue was $6.4 million, up from $1.4 million in Q2 2023, mainly from BARDA contract work.

• Net loss for Q2 2024 was $16.5 million, improved from $22.6 million in Q2 2023.

• Cash, cash equivalents, and investments totaled $62.6 million as of June 30, 2024; an additional $64.7 million received post-quarter from BARDA.

• Operating expenses decreased 7% year-over-year to $22.7 million in Q2 2024, with R&D at $17.5 million and G&A at $5.2 million.

• H1 2024 revenue was $8.6 million, up from $2.0 million year-over-year.

Outlook and guidance

• Cash runway expected to extend into 2026 based on current plans and recent BARDA funding.

• Phase IIb COVID-19 trial expected to initiate in the second half of 2024, pending FDA alignment.

• Ongoing engagement with FDA for both COVID-19 and norovirus programs, with updates to be provided as warranted.

• Interim efficacy analysis planned after 255 symptomatic COVID-19 cases; primary analysis after 12 months post-vaccination.

• Additional capital needs may arise depending on future development and commercialization progress.